A viral transduction enhancer is a reagent that improves the efficiency of viral gene delivery into target cells. These reagents help increase interactions between viral particles and cells, resulting in higher transduction rates and improved expression of delivered genetic material.

ViralEntry™ Transduction Enhancer is a proprietary reagent developed to improve viral transduction efficiency in a wide range of mammalian cell types. It is designed for use with lentiviral and retroviral vectors and has demonstrated substantial improvements in transduction efficiency in both adherent and suspension cell cultures.

ViralEntry™ enhances the interaction between viral particles and target cells, increasing the likelihood of successful viral entry. This results in higher transduction efficiencies and improved expression of delivered transgenes while maintaining excellent cell viability.

ViralEntry™ is optimized for lentiviral and retroviral transduction applications. It can be used for gene overexpression, gene knockdown, CRISPR-based gene editing, pooled screening applications, stable cell line generation, and cell engineering workflows.

Yes. ViralEntry™ was specifically developed to improve lentiviral transduction efficiency and is compatible with research-grade lentiviral vector systems.

Yes. ViralEntry™ can improve retroviral transduction efficiency in many cell types and may be used as part of standard retroviral gene delivery workflows.

ViralEntry™ has been successfully used with HEK293, HEK293T, CHO, Jurkat, K562, NIH3T3, primary T cells, primary B cells, stem cells, macrophages, and other difficult-to-transduce mammalian cells.

Yes. Primary T cells are often challenging to transduce efficiently. ViralEntry™ can significantly improve lentiviral transduction efficiency in activated primary T cells, making it useful for CAR-T development, TCR engineering, and other cell therapy research applications.

Yes. Primary B cells are traditionally among the most difficult mammalian cell types to transduce. ViralEntry™ was developed to improve transduction efficiency in B-cell applications where standard methods may provide limited success.

Yes. ViralEntry™ may be used with pluripotent stem cells, induced pluripotent stem cells (iPSCs), and adult stem cells where enhanced viral delivery is desired.

Yes. ViralEntry™ is particularly useful for suspension cell lines and primary suspension cultures that often exhibit lower transduction efficiencies than adherent cells.

Yes. ViralEntry™ is compatible with lentiviral CRISPR delivery systems used for gene knockout, CRISPR activation (CRISPRa), CRISPR interference (CRISPRi), pooled screening, and genome engineering applications.

Yes. Improved transduction efficiency often results in a greater proportion of successfully modified cells, simplifying stable cell line generation.

Polybrene is commonly used to improve viral transduction but may cause cytotoxicity, altered cell growth, or cell aggregation in sensitive cell types. ViralEntry™ was developed as a next-generation alternative that provides robust transduction enhancement while maintaining compatibility with a broad range of cell types.

Low transduction efficiency can result from insufficient viral titer, poor cell health, suboptimal MOI, improper timing, inefficient viral entry, or the inherent resistance of certain cell types. Using a transduction enhancer such as ViralEntry™ may significantly improve infection efficiency.

Difficult-to-transduce cells are cells that exhibit poor susceptibility to viral infection under standard conditions. Examples include primary T cells, primary B cells, stem cells, macrophages, dendritic cells, hematopoietic cells, and some suspension cell lines.

Yes. Macrophages are often resistant to efficient viral transduction. ViralEntry™ can improve gene delivery efficiency in macrophage research applications.

When used according to the recommended protocol, ViralEntry™ is designed to provide enhanced transduction efficiency while maintaining high cell viability.

Yes. ViralEntry™ is commonly used in CAR-T development, T-cell receptor engineering, gene therapy vector evaluation, immune cell engineering, and related cell therapy research applications.

Yes. ViralEntry™ supports both transient expression experiments and workflows intended to generate stable genetically modified cell populations.

Applications that commonly benefit include lentiviral transduction, retroviral transduction, stable cell line generation, CRISPR screening, gene overexpression studies, shRNA knockdown experiments, CAR-T development, stem cell engineering, and primary cell modification.